Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for adult glioblastoma has been reported in the published literature.
26 clinical trials registered, 15 recruiting. Interventions under study include procedural interventions, drug therapy, biologic therapy, and other interventions. Pipeline includes 3 PHASE3, 6 PHASE2, 5 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06118723](https://clinicaltrials.gov/study/NCT06118723) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 1:48 PM UTC
Common questions about adult glioblastoma
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) |
— |
Jasper Gerritsen |
RECRUITING |
[NCT04427384](https://clinicaltrials.gov/study/NCT04427384) | Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | RECRUITING |
[NCT06740955](https://clinicaltrials.gov/study/NCT06740955) | Hypofractionated Radiotherapy | NA | The First Hospital of Jilin University | RECRUITING |
[NCT06805305](https://clinicaltrials.gov/study/NCT06805305) | DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | PHASE2 | Diakonos Oncology Corporation | RECRUITING |
[NCT06954636](https://clinicaltrials.gov/study/NCT06954636) | Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study | — | Sied Kebir | RECRUITING |
229 publications have been identified in PubMed for adult glioblastoma. Research spans Review / Meta-Analysis (45%), Basic Science / Preclinical (27%), and Diagnostic / Biomarker (10%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 102 | 45% |
Laboratory research | 61 | 27% |
Testing and diagnosis research | 22 | 10% |
Disease patterns and progression | 12 | 5% |
Clinical study results | 11 | 5% |
New treatment approaches | 11 | 5% |
Patient case studies | 7 | 3% |
Other research | 3 | 1% |
Harper SD (2026). [PMID: 41972763](https://pubmed.ncbi.nlm.nih.gov/41972763/). *Neurosurgery*. [Clinical Trial Publication]
Hug E (2026). [PMID: 42005556](https://pubmed.ncbi.nlm.nih.gov/42005556/). *Int J Part Ther*. [Review / Meta-Analysis]
Li H (2026). [PMID: 42220491](https://pubmed.ncbi.nlm.nih.gov/42220491/). *Front Immunol*. [Case Report / Case Series]
Menaceur Vandenbroucke C (2026). [PMID: 41492781](https://pubmed.ncbi.nlm.nih.gov/41492781/). *Brain*. [Review / Meta-Analysis]
Shirota M (2026). [PMID: 40991528](https://pubmed.ncbi.nlm.nih.gov/40991528/). *Neuroradiol J*. [Review / Meta-Analysis]
Soumbasis A (2026). [PMID: 41310975](https://pubmed.ncbi.nlm.nih.gov/41310975/). *Brain*. [Review / Meta-Analysis]
Cheng HS (2026). [PMID: 41502293](https://pubmed.ncbi.nlm.nih.gov/41502293/). *Curr Opin Clin Nutr Metab Care*. [Review / Meta-Analysis]
Tsoneva DK (2026). [PMID: 42004686](https://pubmed.ncbi.nlm.nih.gov/42004686/). *J Liq Biopsy*. [Diagnostic / Biomarker]
Wasiak T (2026). [PMID: 41677672](https://pubmed.ncbi.nlm.nih.gov/41677672/). *Cells*. [Review / Meta-Analysis]
Harper SD (2026). [PMID: 41976404](https://pubmed.ncbi.nlm.nih.gov/41976404/). *Cancers (Basel)*. [Review / Meta-Analysis]
AI-curated news mentioning adult glioblastoma
Updated Sep 10, 2026
Sapanisertib shows promise for treating rare mTOR-driven disorders, with potential applications in various cancers including bladder and ovarian cancer. Successful late-stage clinical development could unlock orphan-drug incentives and enhance adoption in specialized treatment centers.
A study from EORTC 1419 (ETERNITY) examines neurocognitive functioning in long-term survivors of glioblastoma and astrocytoma, providing insights into the cognitive impacts of these CNS tumors. The findings contribute to understanding the long-term effects of these aggressive cancers on patient quality of life.
A case study highlights the successful multimodal treatment of a rare dual fungal brain abscess, which mimicked glioblastoma in an immunocompetent patient. This research contributes to the understanding of differential diagnoses in brain lesions.
Recent research highlights the development of magneto-NIR-II-programmed cascade nanozymes that facilitate blood-brain barrier translocation and enhance autophagic resistance in glioblastoma. This innovative approach could pave the way for more effective treatments targeting this aggressive brain tumor.